Brain
Protocol: NCCTG-N0574:
A Phase III Randomized Trial of the Role of the Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with 1 to 3 Cerebral Metastases
PI: Ron Allison, MD
Breast
Protocol: NSABP FRP FB-5:
A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2 Positive Pathologic Stage III Breast Cancer
PI: Darla Liles, MD
Protocol: ECOG 40101:
A Phase III Randomized Study of Cyclophosamide and Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy For Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes
PI: Darla Liles, MD
Protocol: NSABP B-42:
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
PI: Darla Liles, MD Protocol: ECOG TAILORx Trial:
PACCT-1 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
PI: Darla Liles, MD
Protocol: UMCIRB# 06-400:
Barriers to Accrual to Clinical Trials for Breast Carcinoma in Minority Women in Eastern North Carolina
PI: Darla Liles, MD
Protocol: ImmunoGen DS-6:
Analysis of Shed DS6 (CA6) in Breast Cancer Patient Plasma Samples
PI: Darla Liles, MD
Protocol: LJCC 07-03:
A Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple Negative Breast Cancer
PI: Paul Walker, MD
Gastrointestinal Colon
None At This Time
Gastric
Protocol: ECOG 80101:
Phase III Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or Gastroesophageal Adenocarcinoma
PI: Ron Allison, MD
Genitourinary Renal
Protocol: LJCC 07-02:
ECU Experience with Inpatient Interleukin-2 in Kidney Cancer and Melanoma
PI: Walter Quan, MD
Prostate
Protocol: RTOG 0521:
A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer.
PI: Roger Ove, MD
Gynecologic Cervical
Protocol: AVF3963s:
Neoadjuvant bevacizumab and carboplatin followed by concurrent bevacizumab, carboplatin and pelvic radiation therapy in the primary treatment of cervix cancer
PI: Hiram Gay, MD
Protocol: GOG 204:
A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
PI: Howard Homesley, MD
Endometrial
Protocol: GOG 209:
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Vs Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
PI: Howard Homesley, MD
Protocol: GOG 210:
A Molecular Staging Study of Endometrial Carcinoma
PI: Howard Homesley, MD
Ovarian
Protocol: AVF4095g:
A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitie Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma
PI: Howard Homesley, MD
Protocol: Novartis CEPO906A2303:
A Randomized, Parallel Group, Open-Label, Active Controlled, Multicenter Phase III Trial Of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin (Doxil?/Caelyx?) In Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Or Primary Peritoneal Cancer
PI: Howard Homesley, MD
Protocol: OVATURE (OVArian TUmor REsponse Study):
Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination w/Carboplatin vs. Carboplatin w/Placebo in Patients w/Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least 2nd Line Platinum Therapy
PI: Howard Homesley, MD
Protocol: PML 0239:
A PILOT Phase 2 Study Evaluating the Combination of Oxaliplatin and Docetaxel w/Bevacizumab as 1st Line Therapy in Patients w/FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma
PI: Howard Homesley, MD
Head and Neck
Protocol: RTOG 0522:
A Randomized Phase III Trial of Concurrent Accelerated Radiation & Cisplatin vs. Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III & IV Head and Neck Carcinomas
PI:Roger Ove, MD
Hemophilia
Hemophilia: SPINART:
A Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis w/rFVIII Therapy in Severe Hemophilia A Adult Subjects Compared to that of Episodic Treatment
PI: Darla Liles, MD
Hematological Leukemia
Protocol: Trisenox:
An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination with Arsenic Trioxide Compared with Low-Dose Cytarabine Alone for the Treatment of Elderly Patients with Acute Myeloid Leukemia (AML)
PI: Adam Asch, MD
Protocol: LJCC 06-05:
Phase II Trial Of Daily Pulse Interleukin-2 With Famotidine In Acute Myelogenous Leukemia
PI: Paul Walker, MD
Protocol: # 05-0388:
Chemotherapy Induced Mucositis and Alopecia During Induction Therapy for Acute Myelogenous Leukemia
PI: Darla Liles, MD
Liver
Protocol: TheraSphere Device:
A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma - HDE#980006
PI: Suzanne Russo, MD
Lymphoma Protocol: ECOG E4402:
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin’s Lymphoma
PI: Charles Knupp, MD
Lung Non-small cell
Protocol: LJCC 07-01:
Phase II Trial of Pulsed Paclitaxel with Concurrent Thoracic Radiotherapy and Adjuvant Gemcitabine and Carboplatin in Stage IIIA and IIIB non-Small Cell Lung Cancer
NCI Listing
PI: Hiram Gay, MD
Protocol: MAGRIT 109493:
A Double Blind, Randomized, Placebo Controlled Phase III Study to Assess the Efficacy of recMAGEA3 + AS15 Antigen-Specific Ca Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive NSCLC
PI: Paul Walker, MD
Protocol: RTOG 0229:
A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma
PI: Ron Allison, MD
Melanoma
Protocol: LJCC 07-02:
ECU Experience with Inpatient Interleukin-2 in Kidney Cancer and Melanoma
PI: Paul Walker, MD
Protocol: SYMMETRY:
Randomized, Double-Blinded, Phase III Trial of STA-4783 in Combination with Paclitaxel vs. Paclitaxel Alone for treatment of Chemotherapy - Naive Subjects with Stage IV Metastatic Melanoma
PI: Paul Walker, MD
Pancreatic
Protocol:
A Phase II Study of Direct Tumor Injection of TNFerade Followed by KLH-pulsed Autologous Dendritic Cells in Patients with Unresectable Pancreatic Cancer
PI: Emmanuel Zervos, MD
Protocol:
A Randomized Phase II/III Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
PI: Emmanuel Zervos, MD
Protocol:
A Phase II Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; and Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation for Ras Mutation
PI: Emmanuel Zervos, MD
Photodynamic Therapy Protocol: PDT ENT:
Photodynamic Therapy in Dysplasia and Carcinoma-in-Situ of the Aero-Digestive tract
PI: Ron Allison, MD
Protocol: MKA Grant:
Fluorescence Detection Imaging of Breast Cancer Chest Wall Recurrence for Photodynamic Therapy Treatment Field Identification
PI: Rosa Cuenca, MD
